We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Checkpoint Protein Expression in Tumor Microenvironment Defines Prognosis of Hodgkin Lymphoma Patients

By LabMedica International staff writers
Posted on 04 Jan 2022
In Hodgkin lymphoma, B-lymphocytes start to multiply in an abnormal way and begin to collect in certain parts of the lymphatic system, such as the lymph nodes (glands). More...
The affected lymphocytes lose their infection-fighting properties, making one more vulnerable to infection.

In classical Hodgkin lymphoma (cHL), sparse malignant Hodgkin Reed-Sternberg (HRS) cells are embedded into extensive tumor microenvironment (TME) consisting mostly of benign immune cells, such as T and B lymphocytes, macrophages, eosinophils, plasma cells, and mast cells.

Clinical Scientists at the Helsinki University Hospital (Helsinki, Finland) and their colleagues studied clinical data and formalin-fixed paraffin-embedded (FFPE) diagnostic tumor tissue samples from patients with primary cHL diagnosed between years 1993- 2012 and treated or followed. The patients were divided into two cohorts: the first cohort, “gene expression cohort”, consisted of 88 patients, and the second cohort, “immunohistochemistry (IHC) cohort”, of 131 patients.

The scientists used the NanoString nCounter digital gene expression profiling with 770-gene PanCancer Immune Profiling Panel (XT-CSO-HIP1-12, NanoString Technologies, Seattle, WA, USA) for gene expression profiling. To assess the proportions of the distinct immune cells in the TME, they applied CIBERSORT (Stanford University, Stanford, CA, USA) for the gene expression cohort, and multiplex immunohistochemistry to characterize the immunoprofile of cHL TME, and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and non-inflamed TME. Several macrophage-related genes were upregulated in samples with the non-T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages.

The investigators reported that a cluster with high proportions of checkpoint protein (PD-1, PD-L1, IDO-1, LAG-3, and TIM-3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs. 96%), and remained as an independent prognostic factor for OS in multivariable analysis (HR 4.34). cHLs with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples and in an expansion cohort of 84 cHL relapse samples.

The authors concluded that their findings provide novel, more accurate information on the composition of different immune cells, checkpoint molecules, and their relationship in the heterogeneous cHL TME. Furthermore, the data recognize the prognostic impact of T cell and Tumor-Associated Macrophage (TAM) mediated checkpoint molecules on the survival of cHL patients. The study was published on December 23 2021 in the journal Blood Advances.

Related Links:
Helsinki University Hospital
NanoString Technologies
CIBERSORT



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.